SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 38,006 Shares of Company Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 38,006 shares of the stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $20.05, for a total transaction of $762,020.30. Following the completion of the sale, the chief executive officer owned 379,256 shares of the company’s stock, valued at approximately $7,604,082.80. The trade was a 9.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Laura Francis also recently made the following trade(s):

• On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The stock was sold at an average price of $20.12, for a total value of $522,556.64.
• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $78,538.46.
• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64.

SiBone Price Performance

Shares of NASDAQ:SIBN opened at $19.47 on Thursday. The firm has a market capitalization of $863.48 million, a PE ratio of -57.26 and a beta of 0.66. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. SiBone has a 1-year low of $11.48 and a 1-year high of $21.89. The business’s 50 day moving average is $18.92 and its 200-day moving average is $16.47.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million during the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. Sell-side analysts predict that SiBone will post -0.40 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on SIBN shares. TD Cowen increased their price objective on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. UBS Group raised their price objective on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Finally, Truist Financial lifted their target price on shares of SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.50.

Hedge Funds Weigh In On SiBone

A number of hedge funds have recently modified their holdings of SIBN. Versant Capital Management Inc lifted its holdings in shares of SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after acquiring an additional 887 shares during the period. D.A. Davidson & CO. grew its holdings in shares of SiBone by 5.7% in the 1st quarter. D.A. Davidson & CO. now owns 36,882 shares of the company’s stock worth $466,000 after purchasing an additional 1,991 shares during the last quarter. Diversified Trust Co grew its holdings in shares of SiBone by 10.8% in the 1st quarter. Diversified Trust Co now owns 24,335 shares of the company’s stock worth $307,000 after purchasing an additional 2,375 shares during the last quarter. State of Wyoming grew its holdings in shares of SiBone by 70.8% in the 1st quarter. State of Wyoming now owns 10,832 shares of the company’s stock worth $137,000 after purchasing an additional 4,490 shares during the last quarter. Finally, Quantinno Capital Management LP increased its position in shares of SiBone by 58.2% during the 1st quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock worth $372,000 after purchasing an additional 10,848 shares in the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

About SiBone

SI-BONE, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of disorders affecting the sacroiliac joint, which connects the spine to the pelvis. The company’s technology is intended to support minimally invasive procedures for patients with sacroiliac joint dysfunction and related conditions.

Its product portfolio includes the iFuse Implant System, a family of triangular titanium implants designed to stabilize and fuse the sacroiliac joint.